Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple IV autologous bone marrow-derived mesenchymal stem cells in ALS
jRCT2033240715Recruiting
- Sponsor
- Nipro Corporation
- Start
- Apr 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of autologous bone marrow-derived human mesenchymal stem cells in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Nipro Corporation. Primary endpoint: Change in ALSFRS-R score (primary analysis). Started Apr 2025; status: recruiting.
02
Drugs
autologous bone marrow-derived human mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2033240715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240715.